Loading...
•
Dec 31, 2021
Tourmaline Bio Q4 2021 Earnings Report
Reported financial results for the quarter and year ended December 31, 2021.
Key Takeaways
Talaris Therapeutics reported a net loss of $14.2 million for Q4 2021 and finished the quarter with $244 million in cash, cash equivalents and marketable securities. The company continues to advance its clinical programs, including the Phase 3 FREEDOM-1 trial and the newly initiated Phase 2 FREEDOM-2 and FREEDOM-3 trials.
Presented initial positive data update from the ongoing Phase 3 (FREEDOM-1) clinical trial of FCR001 in LDKT.
Presented confirmatory data analysis from the Phase 2 trial demonstrating FCR001 induced durable tolerance in highly mismatched related and unrelated recipients with living donor kidney transplant (LDKT).
Initiated Phase 2 (FREEDOM-3) clinical trial of FCR001 in scleroderma, its first severe autoimmune disease.
Talaris finished Q4 2021 with $244.0 million in cash, cash equivalents and marketable securities.
Forward Guidance
Talaris is advancing its clinical programs and anticipates providing additional updates on FREEDOM-1 in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...